Pfau, Maximilian <br/><br/>
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.  [electronic resource] 

 -  Ophthalmic research  2015 
 - 150-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1423-0259 
<br/><br/><label>Standard No.: </label>10.1159/000439223  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Drug Substitution<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Macular Edema--drug therapy<br/>Male<br/>Ranibizumab--therapeutic use<br/>Receptors, Vascular Endothelial Growth Factor--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Retina--pathology<br/>Retinal Vein Occlusion--complications<br/>Retrospective Studies<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--drug effects